#5 - BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) specializes in developing drugs for patients with serious and life-threatening rare diseases and medical conditions. As of November 2024, the company has eight products in market with an additional 11 candidates in clinical trials.
BMRN stock is down 31.8% in 2024 despite posting quarterly revenue (18%) and earnings (82%) that are sharply higher year-over-year. However, skeptics will readily point out that the company disappointed earnings expectations by 29%.
That's enough to fuel concerns about the company’s valuation (it’s trading at around 27x forward earnings) and how soon its pipeline will start generating revenue. On the other hand, the stock is showing signs of being oversold, and analysts are calling for a 29% increase in earnings in the next 12 months. BMRN has a Moderate Buy rating with a $94.16 price target that would be a 42% gain for investors.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Read More - Current Price
- $65.60
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 15 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $94.16 (43.5% Upside)
